Navigation Links
Medicure's MEND-CABG Trial Results Published in Peer Reviewed,Journal

tion therefore would have a significant positive impact on patients undergoing CABG surgery. Given the limited success of prophylactic drug therapy for atrial fibrillation, the beneficial effects of MC-1 are promising and warrant further evaluation in future studies."

About MEND-CABG

The MEND-CABG trial, completed in 2006, was a Phase 2 study involving 901 patients that evaluated MC-1 versus placebo in individuals undergoing CABG surgery at 42 investigational sites throughout Canada and the United States.

The 250 mg dose of MC-1 had a 37.2% reduction in the composite of cardiovascular death, non-fatal myocardial infarction (peak CK-MB ?100ng/ml), and non-fatal stroke versus placebo (p@028).

The reduction in the composite endpoint was driven by a significant 46.9% decrease in the incidence of non-fatal myocardial infarction (peak CK-MB ?100ng/ml) with the 250 mg dose of MC-1 versus placebo (p@008).

The clinical results reported at POD 30 were maintained throughout the 90 day follow-up period (POD 90). Safety analysis included in the MEND-CABG study demonstrated that MC-1 was well tolerated. No safety concerns were identified; the incidence of adverse events in the study was comparable across both treatment and control groups.

The MEND-CABG trial was the catalyst to Medicure's ongoing Phase 3 MEND-CABG II study.

About MEND-CABG II

The Phase 3 MEND-CABG II is a double-blind, randomized, placebo-controlled clinical trial that will enroll up to 3,000 patients undergoing CABG surgery at approximately 120 cardiac surgical centers throughout North America and Europe. Study patients will be randomized to receive placebo or MC-1 250 mg prior to surgery and for 30 days post operatively (POD 30). The primary efficacy endpoint of MEND-CABG II is the reduction in the composite of cardiovascular death and non-fatal myocardial infarction up to POD 30. Study patients will be followed for 60 days after treatment (90 days post op
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Medicure MEND CABG Trial Results Published Peer Reviewed Journal
(Date:9/2/2014)... Conn. , Sept. 2, 2014  Numotion is pleased ... the Company,s Board of Directors. Mark is ... number of leadership positions across the organization and was a ... Corporate Executive Council. Mark spent many years running business units ... CEO of GE Healthcare Americas. "We are ...
(Date:9/2/2014)... 2014 Reportlinker.com announces that a new ... Asia-Pacific Infusion Therapy Device Market ... Abstract: The Asia-Pacific ... infusion pumps, syringe infusion pumps, disposable infusion pumps, ... categories are segmented based on the type of ...
(Date:9/2/2014)... YORK , Sept. 2, 2014  Reportlinker.com announces ... its catalogue: Chinese and Taiwanese Markets ... http://www.reportlinker.com/p02353211/Chinese-and-Taiwanese-Markets-for-Minimally-Invasive-Spinal-Devices.html The market for ... and Emerging region is growing at a fast ... most striking growth is happening in China ...
Breaking Medicine Technology:Asia-Pacific Infusion Therapy Device Market 2Asia-Pacific Infusion Therapy Device Market 3Asia-Pacific Infusion Therapy Device Market 4Asia-Pacific Infusion Therapy Device Market 5Asia-Pacific Infusion Therapy Device Market 6Asia-Pacific Infusion Therapy Device Market 7Asia-Pacific Infusion Therapy Device Market 8Asia-Pacific Infusion Therapy Device Market 9Asia-Pacific Infusion Therapy Device Market 10Asia-Pacific Infusion Therapy Device Market 11Asia-Pacific Infusion Therapy Device Market 12Asia-Pacific Infusion Therapy Device Market 13Asia-Pacific Infusion Therapy Device Market 14Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 2Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 3Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 4Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 5Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 6Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 7Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 8Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 9
... the Most Widely Prescribed Drug for Parkinson,s Disease, ... According to a New Report from Decision Resources, ... the,world,s leading research and advisory firms focusing on pharmaceutical ... Parkinson,s,disease patients do not receive any drug treatment in ...
... Group Backs Construction of Facility, VIENNA, Va., Aug. ... that it has entered into an agreement with a,biomedical ... use of,a dedicated manufacturing facility for its cancer drug ... about $15 million. This,facility is located near Baltimore, Maryland. ...
Cached Medicine Technology:Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis 2Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis 3CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 2CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 3CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 4
(Date:9/2/2014)... Recently, BambooIndustry.com, an excellent company in ... strand woven bamboo floors to celebrate the ... its appreciation to the frequent callers, BambooIndustry.com launched a ... addition to strand woven floors, BambooIndustry.com provides many kinds ... floors, click strand woven floors, click lock floors, wide ...
(Date:9/2/2014)... EDT): In a Viewpoint published today in the ... of Boston researchers call for the implementation of taxes ... States. The researchers from the Friedman School of Nutrition ... Boston Children,s Hospital write that policies taxing nearly all ... people make meaningful dietary changes and substantially reduce health ...
(Date:9/2/2014)... 2014 TCG, a leading government technology strategy ... one of the fastest-growing companies in America for the seventh ... was previously recognized in 2013, 2012, 2011, 2010, 2009, 2008, ... grown 86% from 2010 to 2013, ranking the company at ... in America - up 635 spots from 2013! More information ...
(Date:9/2/2014)... 2014 The use of Xarelto (known ... growing at a rapid pace, even as Xarelto ... around the U.S., Bernstein Liebhard LLP reports. According to ... within a year of its 2011 launch, patients were ... a blood thinner that has been in use for ...
(Date:9/2/2014)... Complications are rare among breast cancer patients who ... However, the researchers did find that a ... risk for certain complications than a single mastectomy. ... cancer patients who had a single (64 percent) ... were followed for 30 days after surgery. ...
Breaking Medicine News(10 mins):Health News:Cheap Strand Woven Bamboo Floors For Autumn On Sale At BambooIndustry.com 2Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2
... , ... holidays. Overindulge, that is; on eggnog, cookies, candy and holiday buffet fare ... not to do the same with our four-legged, furry companions. The advent ... a healthier lifestyle for our pets, according to the experts at ...
... , WASHINGTON, Dec. 22 After taking ... Harry Reid and Senators Max Baucus (D-MT), Christopher Dodd (D-CT) ... bill, the Chairperson and President of the National Puerto Rican ... CEO Rafael A. Fantauzzi: , "We are on the ...
... between 2000 and 2005, a trend that could seriously impact ... if it continues, according to a study led by researchers ... Berkeley. The findings are troubling, said the authors, ... of disability rates among older adults may have ended. Adding ...
... cellulose produced by bacteria could be used for artificial blood ... of blood clots than the synthetic materials currently used for ... the University of Gothenburg, Sweden. Produced by a bacterium ... enough to cope with blood pressure and works well with ...
... suffering through a head cold knows, food tastes wrong when ... conclude that the sense of taste operates normally only when ... that the taste system influences olfactory perception, however, has been ... Nature Neuroscience , Brandeis researchers report just such an ...
... ... free treatment e-cards to the military and their families , ... Philadelphia (PRWEB) December 22, 2009 -- ... online holiday program advancing the company,s commitment to offer scientifically-based sound therapy downloads without ...
Cached Medicine News:Health News:Pets Resolve to 'Get Off On the Right Paw' in 2010 With a Healthy, Natural Diet and Exercise 2Health News:Pets Resolve to 'Get Off On the Right Paw' in 2010 With a Healthy, Natural Diet and Exercise 3Health News:Pets Resolve to 'Get Off On the Right Paw' in 2010 With a Healthy, Natural Diet and Exercise 4Health News:National Puerto Rican Coalition Urges Passage of Senate Health Bill 2Health News:Disability may be on the rise again after 20-year decline 2Health News:Disability may be on the rise again after 20-year decline 3Health News:Got taste? 2Health News:Prescription Audio Gives the Gift of Stress Relief This Holiday Season 2Health News:Prescription Audio Gives the Gift of Stress Relief This Holiday Season 3
... the PROTG® GPS™ Self-Expanding Nitinol ... delivered on a commitment to ... PROTG GPS Stents take that ... by adding tantalum markers at ...
Colloidal Gold Conjugated, Streptavidin - 12 OD...
Patent Pending lateral flow assay platform that contributes to increased sensitivty...
Gold Labeling kit for antibodies, the Coat-Block-Run Conjugation Kit pH 8-11; contains 1 bottle each of 20 nm and 40 nm Naked Gold...
Medicine Products: